A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

To join this study, you must have been recently diagnosed with diffuse large B-cell lymphoma (DLBCL) and not yet had any treatment for it. Your diagnosis needs to be confirmed by a specialist. Doctors will also check that your cancer shows up on a special scan called a PET scan.

There are also some general health requirements. For example, your heart should be healthy enough, and if you have conditions like HIV or hepatitis B/C, they need to be well-managed. You should generally be able to manage your daily activities without much difficulty. The study is open to both men and women, aged 18 and over.

However, some things would prevent you from joining. For instance, if your DLBCL started from another, less aggressive type of lymphoma, or if you have a specific type called primary mediastinal B-cell lymphoma. If you have severe heart problems, nerve damage, or certain other serious health issues, you might not be able to participate. Also, you shouldn't have received a live vaccine recently.

If you decide to take part, you would receive either the new treatment combination (zilovertamab vedotin plus R-CHP) or the standard treatment (R-CHOP). The treatments involve a series of cycles, which means you'll have specific medications given over a period, followed by a break, and then another round of treatment. The medicines are given in different ways, some through a drip (intravenous) and some as tablets.

You would have regular visits to the clinic for your treatments, blood tests, physical exams, and scans (like PET scans) to check how you're responding to the treatment and to monitor your general health. There would also be follow-up appointments after your main treatment period ends to keep an eye on your long-term health.

The total duration of the study participation, including treatment and follow-up, can vary for each person but generally involves several months of active treatment and ongoing monitoring for a longer period.